In contrast, MTX, an anti-inflammatory drug that is widely used to treat patients with RA and psoriatic arthritis, did not reduce inflammatory markers, such as interleukin-1, interleukin-6, C-reactive protein, or cardiovascular events in the CIRT trail (Ridker et al., 2019). Here, IL6 is linked to rheumatoid arthritis.